title: [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
authors.forename: Cristina
authors.initials: C
authors.lastname: Martínez Pascual
authors.forename: Mariano
authors.initials: M
authors.lastname: Valdés Mas
authors.forename: Jesús Miguel
authors.initials: JM
authors.lastname: de la Peña Moral
authors.forename: Manuel
authors.initials: M
authors.lastname: Miras López
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000601:surgery; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D017114:Liver Failure, Acute / Q000139:chemically induced* / Q000601:surgery; D016031:Liver Transplantation; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib